3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Melanoma
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Cancer
1
Liver Neoplasms
1
Liposarcoma
1
Kidney Neoplasms
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
lanreotide
3
cabozantinib
3
Nivolumab
3
Everolimus
3
pasireotide
2
lutetium Lu 177 dotatate
2
ganitumab
2
Sunitinib
2
Octreotide
2
Erlotinib Hydrochloride
2
Bevacizumab
2
zimberelimab
1
telotristat ethyl
1
recombinant interferon alpha 2b-like protein
1
pertuzumab
1
pembrolizumab
1
nintedanib
1
ibrutinib
1
fosbretabulin
1
epothilone B
1
conatumumab
1
cixutumumab
1
carfilzomib
1
azaspirane
1
aflibercept
1
Temozolomide
1
Somatostatin
1
Random Allocation
1
Ramucirumab
1
Panitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoid Tumor
×
zimberelimab
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled